Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK) - Full Text View

Sponsor:	University of California, San Francisco
Information provided by:	University of California, San Francisco
ClinicalTrials.gov Identifier:	NCT00935363

Purpose

The purpose of this study is to investigate if the drugs rifampin and fluconazole when given together increase the concentrations in the body of the oral diabetes medication glyburide.

Condition	Intervention
Healthy	Drug: glyburide Drug: glyburide + fluconazole Drug: glyburide + rifampin Drug: glyburide + fluconazole + rifampin

Study Type:	Interventional
Study Design:	Basic Science, Randomized, Open Label, Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study

Resource links provided by NLM:

Drug Information available for: Glyburide Rifampin Fluconazole

U.S. FDA Resources

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:

Drug Plasma Levels [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Blood sugar levels [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	12
Study Start Date:	October 2009
Estimated Study Completion Date:	February 2010
Estimated Primary Completion Date:	February 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
glyburide + fluconazole: Experimental	Drug: glyburide + fluconazole single dose oral glyburide single dose iv fluconazole
glyburide + rifampin: Experimental	Drug: glyburide + rifampin single dose oral glyburide single dose iv rifampin
glyburide: Active Comparator	Drug: glyburide single oral dose
glyburide + fluconazole + rifampin: Experimental	Drug: glyburide + fluconazole + rifampin single dose oral glyburide single dose iv fluconazole single dose iv rifampin

Detailed Description:

The purpose of this study is to find out if a drug interaction occurs when glyburide is taken with rifampin and fluconazole. Glyburide is an oral drug commonly used to lower blood glucose levels in diabetic patients. Rifampin is an antibiotic used to treat tuberculosis and a variety of other infections caused by certain germs called bacteria. Both drugs affect a protein found in your liver cells called organic anion transporting polypeptides (OATPs). This protein regulates drugs getting into and out of your body. Fluconazole is commonly used to treat fungal infections like candidiasis, urinary tract infections and a variety of other infections caused by fungi. It interacts with glyburide by affecting your body's ability to breakdown glyburide. Since both rifampin and fluconazole play a role in the way glyburide enters and remains active in the body, we want to find out what effect taking the three drugs together has on the level of glyburide in the blood.

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy adult with no active medical problems or significant chronic diseases as determined by the study doctor based on history, physical exam and laboratory evaluations;
BMI between 18.5 - 30 kg/m2;
Taking no medications 2 weeks before and during the study enrollment, including drugs of abuse, prescription or OTC medications (except acetaminophen);
Subjects must be able to maintain adequate birth control during the study independent of hormonal contraceptive use;
Be able to provide written informed consent and comply with requirements of the study;
Avoid eating grapefruit and drinking grapefruit juice from 7 days before the first study day until completion of the entire study;
Abstinence from alcoholic beverages, caffeinated beverages and orange juice from 6pm the night before a study day until completion of that study day;
Fast from food and beverages at least 8 hours prior to medication dosing;
Be able to read, speak and understand English

Exclusion Criteria:

Subjects on prescription or chronic over-the counter medications (including hormonal contraceptives);
Subjects with known allergy to glyburide and/or rifampin and/or fluconazole;
Subjects who are not homozygous for CYP2C9 *1 (known poor metabolizers);
Subjects with liver failure or LFTs >2x upper limit of normal;
Subjects with clinically significant elevations in SCr, BUN or other screening laboratory tests as determined by study physician;
Subjects with Hct <30 mg/dL;
Subjects who smoke tobacco;
Subjects with ongoing alcohol or illegal drug use;
Subjects who are pregnant, lactating or attempting to conceive;
Subjects unable to maintain adequate birth control during the study;
Subjects unable to follow protocol instructions or protocol criteria.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00935363

Contacts

Contact: Adam Frymoyer, M.D.

415-476-5890

frymoyera@peds.ucsf.edu

Sponsors and Collaborators

University of California, San Francisco

More Information

No publications provided

Responsible Party:	University of California, San Francisco ( Leslie Z. Benet, Ph.D. )
Study ID Numbers:	GlyburideOATP2C9
Study First Received:	July 7, 2009
Last Updated:	July 8, 2009
ClinicalTrials.gov Identifier:	NCT00935363 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, San Francisco:

glyburide
pharmacokinetics
pharmacodynamics
drug interaction
Healthy Volunteers

Additional relevant MeSH terms:

Fluconazole
Glyburide
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Enzyme Inhibitors
Pharmacologic Actions
Antibiotics, Antitubercular

Rifampin
Anti-Bacterial Agents
Hypoglycemic Agents
Antifungal Agents
Therapeutic Uses
Antitubercular Agents
Nucleic Acid Synthesis Inhibitors
Leprostatic Agents

ClinicalTrials.gov processed this record on February 08, 2010